FIELD: biotechnology.
SUBSTANCE: fusion proteins having at least one polypeptide of the human secretory inhibitor of leukocyte proteases (SLPI) operably linked to an immunoglobulin Fc fragment polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:10 are obtained.
EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of neutrophilic serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.
15 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION SERPINE POLYPEPTIDES AND METHODS FOR THEIR APPLICATION | 2012 |
|
RU2642310C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2727452C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| MODIFIED INTERLEUKIN-7 PROTEIN AND METHODS FOR USE THEREOF | 2016 |
|
RU2708160C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF FUNCTIONAL FRAGMENT OF HUMAN IL-1RA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2023 |
|
RU2821896C1 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
